Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Isoniazid | Research

Regional distribution of Mycobacterium tuberculosis infection and resistance to rifampicin and isoniazid as determined by high-resolution melt analysis

Authors: Zhenzhen Wang, Tengfei Guo, Tao Jiang, Zhanqin Zhao, Xiangyang Zu, Long li, Qing Zhang, Yi Hou, Kena Song, Yun Xue

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Identifying the transmission mode and resistance mechanism of Mycobacterium tuberculosis (MTB) is key to prevent disease transmission. However, there is a lack of regional data. Therefore, the aim of this study was to identify risk factors associated with the transmission of MTB and regional patterns of resistance to isoniazid (INH) and rifampicin (RFP), as well as the prevalence of multidrug-resistant tuberculosis (MDR-TB).

Methods

High-resolution melt (HRM) analysis was conducted using sputum, alveolar lavage fluid, and pleural fluid samples collected from 17,515 patients with suspected or confirmed MTB infection in the downtown area and nine counties of Luoyang City from 2019 to 2021.

Results

Of the 17,515 patients, 82.6% resided in rural areas, and 96.0% appeared for an initial screening. The HRM positivity rate was 16.8%, with a higher rate in males than females (18.0% vs. 14.1%, p < 0.001). As expected, a positive sputum smear was correlated with a positive result for HRM analysis. By age, the highest rates of MTB infection occurred in males (22.9%) aged 26–30 years and females (28.1%) aged 21–25. The rates of resistance to RFP and INH and the incidence of MDR were higher in males than females (20.5% vs. 16.1%, p < 0.001, 15.9% vs. 12.0%, p < 0.001 and 12.9% vs. 10.2%, p < 0.001, respectively). The HRM positivity rate was much higher in previously treated patients than those newly diagnosed for MTB infection. Notably, males at the initial screening had significantly higher rates of HRM positive, INH resistance, RFP resistance, and MDR-TB than females (all, p < 0.05), but not those previously treated for MTB infection. The HRM positivity and drug resistance rates were much higher in the urban vs. rural population. By multivariate analyses, previous treatment, age < 51 years, residing in an urban area, and male sex were significantly and positively associated with drug resistance after adjusting for smear results and year of testing.

Conclusion

Males were at higher risks for MTB infection and drug resistance, while a younger age was associated with MTB infection, resistance to INH and RFP, and MDR-TB. Further comprehensive monitoring of resistance patterns is needed to control the spread of MTB infection and manage drug resistance locally.
Literature
1.
go back to reference Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PDMC, et al: Global tuberculosis report 2020 - reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis 2021, 113 Suppl 1. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PDMC, et al: Global tuberculosis report 2020 - reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis 2021, 113 Suppl 1.
2.
go back to reference Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero JA, Carvalho ACC, Chang K-C, Codecasa L, Correia A, Crudu V, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.CrossRefPubMedPubMedCentral Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero JA, Carvalho ACC, Chang K-C, Codecasa L, Correia A, Crudu V, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.CrossRefPubMedPubMedCentral
3.
go back to reference Ullah I, Shah AA, Basit A, Ali M, Khan A, Ullah U, Ihtesham M, Mehreen S, Mughal A, Javaid A. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC Infect Dis. 2016;16:413.CrossRefPubMedPubMedCentral Ullah I, Shah AA, Basit A, Ali M, Khan A, Ullah U, Ihtesham M, Mehreen S, Mughal A, Javaid A. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC Infect Dis. 2016;16:413.CrossRefPubMedPubMedCentral
4.
go back to reference Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–38.CrossRefPubMedPubMedCentral Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–38.CrossRefPubMedPubMedCentral
5.
go back to reference Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, Wu Z, Lin S, Tian J, Liu Q, et al. Transmission of multidrug-resistant mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17(3):275–84.CrossRefPubMed Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, Wu Z, Lin S, Tian J, Liu Q, et al. Transmission of multidrug-resistant mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17(3):275–84.CrossRefPubMed
6.
go back to reference Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;1:CD012768.PubMed Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;1:CD012768.PubMed
7.
go back to reference Ramirez MV, Cowart KC, Campbell PJ, Morlock GP, Sikes D, Winchell JM, Posey JE. Rapid detection of multidrug-resistant mycobacterium tuberculosis by use of real-time PCR and high-resolution melt analysis. J Clin Microbiol. 2010;48(11):4003–9.CrossRefPubMedPubMedCentral Ramirez MV, Cowart KC, Campbell PJ, Morlock GP, Sikes D, Winchell JM, Posey JE. Rapid detection of multidrug-resistant mycobacterium tuberculosis by use of real-time PCR and high-resolution melt analysis. J Clin Microbiol. 2010;48(11):4003–9.CrossRefPubMedPubMedCentral
8.
go back to reference Global, regional, and national burden of tuberculosis, 1990–2016: results from the global burden of diseases, injuries, and risk factors 2016 study. Lancet Infect Dis 2018, 18(12):1329–1349. Global, regional, and national burden of tuberculosis, 1990–2016: results from the global burden of diseases, injuries, and risk factors 2016 study. Lancet Infect Dis 2018, 18(12):1329–1349.
9.
go back to reference Prasad BM, Satyanarayana S, Chadha SS. Lessons learnt from active tuberculosis case finding in an urban slum setting of Agra city, India. Indian J Tuberc. 2016;63(3):199–202.CrossRefPubMed Prasad BM, Satyanarayana S, Chadha SS. Lessons learnt from active tuberculosis case finding in an urban slum setting of Agra city, India. Indian J Tuberc. 2016;63(3):199–202.CrossRefPubMed
10.
go back to reference Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC Public Health. 2019;19(1):165.CrossRefPubMedPubMedCentral Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC Public Health. 2019;19(1):165.CrossRefPubMedPubMedCentral
11.
go back to reference McLaren ZM, Brouwer E, Ederer D, Fischer K, Branson N. Gender patterns of tuberculosis testing and disease in South Africa. Int J Tuberc Lung Dis. 2015;19(1):104–10.CrossRefPubMed McLaren ZM, Brouwer E, Ederer D, Fischer K, Branson N. Gender patterns of tuberculosis testing and disease in South Africa. Int J Tuberc Lung Dis. 2015;19(1):104–10.CrossRefPubMed
12.
go back to reference Snow KJ, Sismanidis C, Denholm J, Sawyer SM, Graham SM. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J 2018, 51(2). Snow KJ, Sismanidis C, Denholm J, Sawyer SM, Graham SM. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J 2018, 51(2).
13.
go back to reference Asgedom SW, Teweldemedhin M, Gebreyesus H. Prevalence of multidrug-resistant tuberculosis and associated factors in ethiopia: a systematic review. J Pathog. 2018;2018:7104921.CrossRefPubMedPubMedCentral Asgedom SW, Teweldemedhin M, Gebreyesus H. Prevalence of multidrug-resistant tuberculosis and associated factors in ethiopia: a systematic review. J Pathog. 2018;2018:7104921.CrossRefPubMedPubMedCentral
14.
go back to reference Chen MP, Miramontes R, Kammerer JS. Multidrug-resistant tuberculosis in the United States, 2011–2016: patient characteristics and risk factors. Int J Tuberc Lung Dis. 2020;24(1):92–9.CrossRefPubMed Chen MP, Miramontes R, Kammerer JS. Multidrug-resistant tuberculosis in the United States, 2011–2016: patient characteristics and risk factors. Int J Tuberc Lung Dis. 2020;24(1):92–9.CrossRefPubMed
15.
go back to reference WHO. revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013;18(16):20455. WHO. revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013;18(16):20455.
17.
go back to reference Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23(3):167–72.CrossRefPubMed Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23(3):167–72.CrossRefPubMed
18.
19.
go back to reference Keikha M, Karbalaei M. High resolution melting assay as a reliable method for diagnosing drug-resistant TB cases: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):989.CrossRefPubMedPubMedCentral Keikha M, Karbalaei M. High resolution melting assay as a reliable method for diagnosing drug-resistant TB cases: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):989.CrossRefPubMedPubMedCentral
20.
go back to reference Liu Z, Gao Y, Yang H, Bao H, Qin L, Zhu C, Chen Y, Hu Z. Impact of hypoxia on drug resistance and growth characteristics of mycobacterium tuberculosis clinical isolates. PLoS ONE. 2016;11(11):e0166052.CrossRefPubMedPubMedCentral Liu Z, Gao Y, Yang H, Bao H, Qin L, Zhu C, Chen Y, Hu Z. Impact of hypoxia on drug resistance and growth characteristics of mycobacterium tuberculosis clinical isolates. PLoS ONE. 2016;11(11):e0166052.CrossRefPubMedPubMedCentral
21.
go back to reference Minero G, Bagnasco M, Fock J, Tian B, Garbarino F, Hansen MF. Automated on-chip analysis of tuberculosis drug-resistance mutation with integrated DNA ligation and amplification. Anal Bioanal Chem. 2020;412(12):-. Minero G, Bagnasco M, Fock J, Tian B, Garbarino F, Hansen MF. Automated on-chip analysis of tuberculosis drug-resistance mutation with integrated DNA ligation and amplification. Anal Bioanal Chem. 2020;412(12):-.
22.
go back to reference Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario AR, Zhu B-P. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017. BMC Infect Dis. 2019;19(1):387.CrossRefPubMedPubMedCentral Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario AR, Zhu B-P. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017. BMC Infect Dis. 2019;19(1):387.CrossRefPubMedPubMedCentral
23.
go back to reference Zhao Y, Ying H, Demei J, Xie J. Tuberculosis and sexual inequality: the role of sex hormones in immunity. Crit Rev Eukaryot Gene Expr. 2012;22(3):233–41.CrossRefPubMed Zhao Y, Ying H, Demei J, Xie J. Tuberculosis and sexual inequality: the role of sex hormones in immunity. Crit Rev Eukaryot Gene Expr. 2012;22(3):233–41.CrossRefPubMed
24.
go back to reference Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123–32.PubMed Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123–32.PubMed
25.
go back to reference Tao N-N, He X-C, Zhang X-X, Liu Y, Yu C-B, Li H-C. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. Int J Infect Dis 2017, 65. Tao N-N, He X-C, Zhang X-X, Liu Y, Yu C-B, Li H-C. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. Int J Infect Dis 2017, 65.
26.
go back to reference Snow KJ, Nelson LJ, Sismanidis C, Sawyer SM, Graham SM. Incidence and prevalence of bacteriologically confirmed pulmonary tuberculosis among adolescents and young adults: a systematic review. Epidemiol Infect. 2018;146(8):946–53.CrossRefPubMed Snow KJ, Nelson LJ, Sismanidis C, Sawyer SM, Graham SM. Incidence and prevalence of bacteriologically confirmed pulmonary tuberculosis among adolescents and young adults: a systematic review. Epidemiol Infect. 2018;146(8):946–53.CrossRefPubMed
27.
go back to reference An Q, Song W, Liu J, Tao N, Liu Y, Zhang Q, Xu T, Li S, Liu S, Li Y, et al. Primary drug-resistance pattern and trend in elderly tuberculosis patients in Shandong, China, from 2004 to 2019. Infect Drug Resist. 2020;13:4133–45.CrossRefPubMedPubMedCentral An Q, Song W, Liu J, Tao N, Liu Y, Zhang Q, Xu T, Li S, Liu S, Li Y, et al. Primary drug-resistance pattern and trend in elderly tuberculosis patients in Shandong, China, from 2004 to 2019. Infect Drug Resist. 2020;13:4133–45.CrossRefPubMedPubMedCentral
28.
go back to reference Marx FM, Fiebig L, Hauer B, Brodhun B, Glaser-Paschke G, Magdorf K, Haas W. Higher rate of tuberculosis in second generation migrants compared to native residents in a metropolitan setting in Western Europe. PLoS ONE. 2015;10(6):e0119693.CrossRefPubMedPubMedCentral Marx FM, Fiebig L, Hauer B, Brodhun B, Glaser-Paschke G, Magdorf K, Haas W. Higher rate of tuberculosis in second generation migrants compared to native residents in a metropolitan setting in Western Europe. PLoS ONE. 2015;10(6):e0119693.CrossRefPubMedPubMedCentral
29.
go back to reference Mizukoshi F, Kobayashi N, Kirikae F, Ohta K, Tsuyuguchi K, Yamada N, Inoue Y, Horiba M, Kawata N, Ichinose A, et al: Molecular epidemiology of drug-resistant mycobacterium tuberculosis in Japan. mSphere 2021, 6(4):e0097820. Mizukoshi F, Kobayashi N, Kirikae F, Ohta K, Tsuyuguchi K, Yamada N, Inoue Y, Horiba M, Kawata N, Ichinose A, et al: Molecular epidemiology of drug-resistant mycobacterium tuberculosis in Japan. mSphere 2021, 6(4):e0097820.
30.
go back to reference Chen H, He L, Huang H, Shi C, Ni X, Dai G, Ma L, Li W. Mycobacterium tuberculosis lineage distribution in Xinjiang and Gansu Provinces, China. Sci Rep. 2017;7(1):1068.CrossRefPubMedPubMedCentral Chen H, He L, Huang H, Shi C, Ni X, Dai G, Ma L, Li W. Mycobacterium tuberculosis lineage distribution in Xinjiang and Gansu Provinces, China. Sci Rep. 2017;7(1):1068.CrossRefPubMedPubMedCentral
31.
go back to reference Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar J-W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77(6):469–78.CrossRefPubMed Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar J-W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77(6):469–78.CrossRefPubMed
32.
go back to reference Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, Kulsange S, Boehme C, Paramsivan CN, Arinaminpathy N. Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: A Retrospective Analysis. PLoS ONE. 2016;11(2):e0150054.CrossRefPubMedPubMedCentral Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, Kulsange S, Boehme C, Paramsivan CN, Arinaminpathy N. Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: A Retrospective Analysis. PLoS ONE. 2016;11(2):e0150054.CrossRefPubMedPubMedCentral
33.
go back to reference Seifert M, Aung HT, Besler N, Harris V, Mar TT, Colman RE, Rodwell TC, Aung ST. Age and sex distribution of mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF. BMC Infect Dis. 2021;21(1):781.CrossRefPubMedPubMedCentral Seifert M, Aung HT, Besler N, Harris V, Mar TT, Colman RE, Rodwell TC, Aung ST. Age and sex distribution of mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF. BMC Infect Dis. 2021;21(1):781.CrossRefPubMedPubMedCentral
34.
go back to reference Chuang P-H, Wu M-H, Fan S-Y, Lin K-Y, Jou R. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007–2014. PLoS ONE. 2016;11(11):e0165222.CrossRefPubMedPubMedCentral Chuang P-H, Wu M-H, Fan S-Y, Lin K-Y, Jou R. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007–2014. PLoS ONE. 2016;11(11):e0165222.CrossRefPubMedPubMedCentral
35.
go back to reference Yao S, Yan J, Li L, Ma D, Liu J, Wang Q, Wang A, Bao F, Zhang Z, Bao X: Determining drug resistance and risk factors for multidrug-resistant tuberculosis in sputum smear-positive tuberculosis outpatients in Anhui Province, China, 2015–2016. Infect Drug Resist 2020, 13:1023–1032. Yao S, Yan J, Li L, Ma D, Liu J, Wang Q, Wang A, Bao F, Zhang Z, Bao X: Determining drug resistance and risk factors for multidrug-resistant tuberculosis in sputum smear-positive tuberculosis outpatients in Anhui Province, China, 2015–2016. Infect Drug Resist 2020, 13:1023–1032.
36.
go back to reference Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, et al: A standardised method for interpreting the association between mutations and phenotypic drug resistance in. Eur Respir J 2017, 50(6). Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, et al: A standardised method for interpreting the association between mutations and phenotypic drug resistance in. Eur Respir J 2017, 50(6).
37.
go back to reference Jagielski T, Bakuła Z, Brzostek A, Minias A, Stachowiak R, Kalita J, Napiórkowska A, Augustynowicz-Kopeć E, Żaczek A, Vasiliauskiene E, et al: characterization of mutations conferring resistance to rifampin in mycobacterium tuberculosis clinical strains. Antimicrob Agents Chemother 2018, 62(10). Jagielski T, Bakuła Z, Brzostek A, Minias A, Stachowiak R, Kalita J, Napiórkowska A, Augustynowicz-Kopeć E, Żaczek A, Vasiliauskiene E, et al: characterization of mutations conferring resistance to rifampin in mycobacterium tuberculosis clinical strains. Antimicrob Agents Chemother 2018, 62(10).
38.
go back to reference Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SMM, Banu S. Comparison of xpert MTB/RIF Assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in mycobacterium tuberculosis. PLoS ONE. 2016;11(4):e0152694.CrossRefPubMedPubMedCentral Rahman A, Sahrin M, Afrin S, Earley K, Ahmed S, Rahman SMM, Banu S. Comparison of xpert MTB/RIF Assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in mycobacterium tuberculosis. PLoS ONE. 2016;11(4):e0152694.CrossRefPubMedPubMedCentral
39.
go back to reference Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Frequency and distribution of tuberculosis resistance-associated mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother. 2016;60(7):3994–4004.CrossRefPubMedPubMedCentral Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Frequency and distribution of tuberculosis resistance-associated mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother. 2016;60(7):3994–4004.CrossRefPubMedPubMedCentral
40.
go back to reference Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3047–53.CrossRefPubMedPubMedCentral Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3047–53.CrossRefPubMedPubMedCentral
Metadata
Title
Regional distribution of Mycobacterium tuberculosis infection and resistance to rifampicin and isoniazid as determined by high-resolution melt analysis
Authors
Zhenzhen Wang
Tengfei Guo
Tao Jiang
Zhanqin Zhao
Xiangyang Zu
Long li
Qing Zhang
Yi Hou
Kena Song
Yun Xue
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07792-7

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.